Bottom line After a comprehensive review, the FDA reported that it did not find an increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonists and requested removal of that warning from labeling for Saxenda, Wegovy, and Zepbound. This is reassuring, but new depression, suicidal thoughts, or major behavioral change still requires
